Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
3.410
+0.070 (2.10%)
At close: Apr 7, 2026, 4:00 PM EDT
3.540
+0.130 (3.81%)
After-hours: Apr 7, 2026, 7:58 PM EDT
Prime Medicine Stock Forecast
Stock Price Forecast
The 4 analysts that cover Prime Medicine stock have a consensus rating of "Buy" and an average price target of $7.56, which forecasts a 121.70% increase in the stock price over the next year. The lowest target is $4.25 and the highest is $11.
Price Target: $7.56 (+121.70%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Prime Medicine stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Initiates $11 | Buy | Initiates | $11 | +222.58% | Mar 12, 2026 |
| Citigroup | Citigroup | Hold Maintains $5 → $4.25 | Hold | Maintains | $5 → $4.25 | +24.63% | Nov 11, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $10 → $9 | Strong Buy | Maintains | $10 → $9 | +163.93% | Nov 10, 2025 |
| Citigroup | Citigroup | Hold Maintains $1.5 → $4 | Hold | Maintains | $1.5 → $4 | +17.30% | Aug 12, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +193.26% | Aug 8, 2025 |
Financial Forecast
Revenue This Year
5.21M
from 4.63M
Increased by 12.41%
Revenue Next Year
7.93M
from 5.21M
Increased by 52.24%
EPS This Year
-0.94
from -1.35
EPS Next Year
-0.91
from -0.94
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 10.5M | 23.1M | |||
| Avg | 5.2M | 7.9M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 126.7% | 343.6% | |||
| Avg | 12.4% | 52.2% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.72 | -0.45 | |||
| Avg | -0.94 | -0.91 | |||
| Low | -1.16 | -1.28 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.